First Time Loading...

GT Biopharma Inc
NASDAQ:GTBP

Watchlist Manager
GT Biopharma Inc Logo
GT Biopharma Inc
NASDAQ:GTBP
Watchlist
Price: 3.18 USD -1.24%
Updated: May 7, 2024
Section:
 

Relative Value

There is not enough data to reliably calculate the relative value of GTBP.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GTBP Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

N/A
P/S
P/S
Price to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-49.5
Median 5Y
-26.1
Industry
26.8
Forward
-0.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-117.3
Median 5Y
-73.4
Industry
23.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-51.6
Median 5Y
-141.8
Industry
21.4
More Details
0.6
P/B
P/B
Price to Book Value
0.6
vs History
68
vs Industry
71
Median 3Y
107.3
Median 5Y
31.3
Industry
2.6
More Details
N/A
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.5
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.2
More Details
0.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
0.7
vs History
1
vs Industry
17
Median 3Y
-49.3
Median 5Y
-36.1
Industry
4.5
More Details
0.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
0.7
vs History
1
vs Industry
15
Median 3Y
-49.3
Median 5Y
-36.1
Industry
4.4
Forward
0.5
More Details
1.1
EV/OCF
EV/OCF
Enterprise Value to OCF
1.1
vs History
1
vs Industry
17
Median 3Y
-115.9
Median 5Y
-73.4
Industry
5.6
More Details
1.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
1.1
vs History
1
vs Industry
13
Median 3Y
-115.9
Median 5Y
-73.4
Industry
3.4
More Details
2.3
EV/IC
EV/IC
Enterprise Value to IC
2.3
vs History
11
vs Industry
48
Median 3Y
-320.7
Median 5Y
-211.8
Industry
5
More Details

Multiples Across Competitors

GTBP Competitors Multiples
GT Biopharma Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
GT Biopharma Inc
NASDAQ:GTBP
4.4m USD 0 -0.6 0.7 0.7
US
Abbvie Inc
NYSE:ABBV
288.1B USD 5.3 59.8 13 19.8
US
Amgen Inc
NASDAQ:AMGN
162.1B USD 5.5 43.1 18.3 30.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
105.9B USD 8.1 27.4 22.2 24.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.8B USD 10.7 29.1 23.2 24.3
AU
CSL Ltd
ASX:CSL
135.1B AUD 6.3 36.2 21.9 27.1
US
Gilead Sciences Inc
NASDAQ:GILD
81.7B USD 3 169.1 6.8 8.9
US
Moderna Inc
NASDAQ:MRNA
46B USD 8.9 -7.7 -8.3 -7.4
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
31.9B USD 3.3 27.2 14 17.5
KR
Celltrion Inc
KRX:068270
40.3T KRW 18.5 75.2 46 63.3
P/E Multiple
Earnings Growth
US
GT Biopharma Inc
NASDAQ:GTBP
Average P/E: 58.4
Negative Multiple: -0.6 		N/A
US
Abbvie Inc
NYSE:ABBV
59.8
405%
US
Amgen Inc
NASDAQ:AMGN
43.1
82%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
27.4
45%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.1
49%
AU
CSL Ltd
ASX:CSL
36.2
84%
US
Gilead Sciences Inc
NASDAQ:GILD
169.1
75%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -7.7 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -57.5 N/A
US
Biogen Inc
NASDAQ:BIIB
27.2
155%
KR
Celltrion Inc
KRX:068270
75.2
105%

See Also

Summary
GTBP intrinsic value, competitors valuation, and company profile.
DCF Valuation
GTBP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GTBP stock valuation using valuation multiples.
Wall Street Estimates
GTBP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GTBP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 135,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.